INFORMAZIONI SU QUESTO EPISODIO
In Part Two of my conversation with Dr Steven Lu, Everlab’s co-founder and Chief Medical Officer, we unpack what’s actually worth measuring, which treatments show real promise, what’s still experimental and what the future of preventative healthcare could look like.
And why, when it comes to optimising our health, we should be problem-centric, not solution-centric.
We dive into:
- What keeps Steven up at night as Everlab grows and expands internationally.
- What’s actually worth measuring: From Lp(a), a genetically influenced cardiovascular risk marker, to body composition, and the tests Steven believes deserve more attention.
- GLP-1s, breakthrough drugs or misunderstood medicine? Their potential, the risks of poor dosing and inadequate support, and why protecting muscle and bone health matters.
- The peptide boom: What’s backed by evidence, the safety and quality concerns, and why Steven isn’t ready to inject them himself. Yet.
- Being problem-centric, not solution-centric: Why chasing the latest tests, treatments and biohacks isn’t necessarily the best approach to better health.
- AI and the future of primary care: How Everlab’s Concierge is bringing AI into healthcare while keeping clinicians in the loop.
- The next frontier of preventative medicine: Pharmacogenetics, personalised care and emerging Alzheimer’s blood tests.
- Hype or worth it? Steven’s rapid-fire take on full-body MRIs, continuous glucose monitors, wearables, NAD+ infusions and creatine, plus the health habits he thinks are overhyped and underappreciated.
Chapters
00:00 Preview: what's real in longevity
01:12 What keeps Steven up at night: leading Everlab through uncharted waters
03:00 What's worth measuring: Lp(a) and body composition
05:28 GLP-1s: what works, and what goes wrong without support
12:13 Peptides: the evidence gap and his "would I take it myself?" test
18:28 Be problem-centric, not solution-centric
22:41 Pharmacogenetics, tailored care and the public system's role
24:03 AI in primary care: keeping a clinician in the loop
27:55 The pTau217 Alzheimer's blood test and what Everlab is studying next
31:06 Rapid fire: MRI, CGMs, wearables, NAD+ and creatine
38:59 Lightning round: favourite emoji, overhyped and underhyped
41:40 Family, where to find Everlab, and thanks
Links and resources
What The Health: https://whatthehealth.io/
Everlab: https://www.everlab.com.au/
Dr Steven Lu at Everlab: https://www.everlab.com.au/doctors
Tenmile Ventures: https://www.tenmile.com/
Mentioned in the episode:
- Everlab Concierge product update (the AI health assistant, Eva, that Steven describes): https://www.everlab.com.au/post/introducing-everlab-concierge
- KFF Health Tracking Poll, November 2025 (12% of US adults say they currently take a GLP-1 drug; 18% have ever taken one): https://www.kff.org/health-costs/poll-1-in-8-adults-say-they-are-currently-taking-a-glp-1-drug-for-weight-loss-diabetes-or-another-condition-even-as-half-say-the-drugs-are-difficult-to-afford/
- TGA, concerns about unapproved peptide products (background to the peptide discussion): https://www.tga.gov.au/news/media-releases/concerns-regarding-public-health-risks-associated-unapproved-peptide-products
- RACGP newsGP, TGA warning on unapproved peptides (April 2026): https://www1.racgp.org.au/newsgp/professional/tga-issues-warning-against-unapproved-peptides
- MSAC Application 1736 (the proposal to list Lp(a) testing on the MBS; outcome pending): https://www.msac.gov.au/applications/1736
- RACGP submission on MSAC Application 1736 (October 2022; opposes the listing): https://www.racgp.org.au/advocacy/reports-and-submissions/view-all-reports-and-submissions/2022-reports-and-submissions/msac-application-1736-lipoprotein-a-testing-as
- AusDoc, Australian Atherosclerosis Society backs the proposed Lp(a) MBS items: https://ausdoc.com.au/specialist-update/cardiologists-back-expanded-lipoproteina-testing-for-at-risk-patients
- Australian Atherosclerosis Society, patient brochure on elevated lipoprotein(a): https://www.athero.org.au/fh/wp-content/uploads/Lpa-brochure.pdf
- Medical Republic on the pTau217 Alzheimer's blood test (Roche test authorised in Australia; the Health Minister's comments): https://medicalrepublic.com.au/mark-butler-and-the-holy-grail-of-dementia-tests/127796
- Axios on OpenAI's report on ChatGPT health use (January 2026; more than 40 million people ask daily): https://axios.com/2026/01/05/chatgpt-openai-health-insurance-aca
- News 12 New York on the death of a woman after an NAD+ infusion at a Bronx wellness centre (the case Steven refers to in the rapid-fire round): https://bronx.news12.com/prosecutors-unauthorized-nad-iv-infusion-led-to-womans-death
Subscribe for more conversations cutting through the noise in health technology, biotech and healthcare innovation.
What the Health is brought to you in partnership with Tenmile Ventures.
What the Health is part of Day One Network: https://dayone.fm/
#HealthTech #Longevity #PreventativeHealth #AIinHealthcare
